Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm

J Immunother Precis Oncol. 2020 Oct 7;3(4):147-156. doi: 10.36401/JIPO-20-18. eCollection 2020 Nov.

Abstract

How cancers are characterized and treated has evolved over the past few decades. Major advances in genomics tools and techniques have revealed interlinked regulatory pathways of cancers with unprecedented detail. Early discoveries led to success with rationally targeted small molecules and more recently with immunomodulatory agents, setting the stage for precision oncology. However, drug resistance to every agent has thus far proven intractable, sending us back to fill the gaps in our rudimentary knowledge of tumor biology. Epigenetics is emerging as a fundamental process in every hallmark of cancer. Large-scale interrogation of the cancer epigenome continues to reveal new mechanisms of astounding complexity. In this review, I present selected experimental and clinical examples that have shaped our understanding of cancer at the molecular level. Translation of our collective erudition into revolutionary diagnostic and treatment strategies will advance the precision oncology paradigm.

Keywords: cancer; epigenomics; epitranscriptomics; genomics; immune checkpoint inhibitors; immuno-oncology; molecular therapy; noncoding RNA; targeted therapy.

Publication types

  • Review

Grants and funding

Source of Support: None.